Aptevo Therapeutics Inc. (APVO)
$4.63
$-0.14
(-2.94%)
As on 18-May-2026 16:00EDT
Market cap
$6 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
1,181,725
10 Years Aggregate
CFO
$-351.76 Mln
EBITDA
$-363.71 Mln
Net Profit
$-330.51 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aptevo Therapeutics (APVO)
| -50.9 | -12.3 | -35.2 | -96.0 | -98.3 | -94.9 | -- |
|
BSE Sensex*
| -11.2 | -4.2 | -10.2 | -8.7 | 7.0 | 8.4 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Aptevo Therapeutics (APVO)
| -99.4 | -98.5 | -92.2 | -70.5 | -78.5 | 300.0 | -48.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aptevo Therapeutics (APVO)
|
4.6 | 5.5 | -0.2 | -26.3 | 12,081.4 | -181.1 | -- | 0.3 |
| 74.0 | 10,799.5 | 622.0 | -300.9 | -30.1 | -62 | -- | 16.7 | |
| 237.6 | 14,697.4 | 867.5 | 506.6 | -2.8 | -- | 26.9 | 25.7 | |
| 75.2 | 10,298.2 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 49.8 | 12,600.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.6 | 6.3 | |
| 95.7 | 12,586.4 | 1,080.2 | -433.2 | -39.8 | -- | -- | 55.7 | |
| 291.8 | 8,707.3 | 417.3 | 225.0 | 42.8 | 18.6 | 39.5 | 7.1 | |
| 522.2 | 11,846.5 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 21.6 | |
| 420.7 | 12,047.6 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26.5 | 20.2 | |
| 320.5 | 9,550.7 | 0.0 | -326.5 | -- | -37.2 | -- | 6.5 |
Shareholding Pattern
View DetailsAbout Aptevo Therapeutics (APVO)
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using... ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Address: 2401 4th Avenue, Seattle, WA, United States, 98121 Read more
-
President, CEO & Director
Mr. Marvin L. White
-
President, CEO & Director
Mr. Marvin L. White
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aptevo Therapeutics (APVO)
What is the current share price of Aptevo Therapeutics Inc (APVO) Today?
The share price of Aptevo Therapeutics Inc (APVO) is $4.63 (NASDAQ) as of 18-May-2026 16:00 EDT. Aptevo Therapeutics Inc (APVO) has given a return of -98.32% in the last 3 years.
What is the current PB & PE ratio of Aptevo Therapeutics Inc (APVO)?
Since, TTM earnings of Aptevo Therapeutics Inc (APVO) is negative, P/E ratio is not available.
The P/B ratio of Aptevo Therapeutics Inc (APVO) is 0.34 times as on 18-May-2026, a 92 discount to its peers’ median range of 4.31 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
1.45
|
0.65
|
|
2021
|
-1.44
|
32.36
|
What is the 52 Week High and Low of Aptevo Therapeutics Inc (APVO)?
The 52-week high and low of Aptevo Therapeutics Inc (APVO) are Rs 258.01 and Rs 3.84 as of 19-May-2026.
What is the market cap of Aptevo Therapeutics Inc (APVO)?
Aptevo Therapeutics Inc (APVO) has a market capitalisation of $ 6 Mln as on 18-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aptevo Therapeutics Inc (APVO)?
Before investing in Aptevo Therapeutics Inc (APVO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.